ArticleFrontiers in molecular biosciences2025
Investigating circulating expression profile for
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative effects of metformin and lifestyle therapy on bone metabolism markers: A 6-month pilot, open-label randomized-clinical trial.Aging clinical and experimental research · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Chronic kidney disease (CKD) incorporates a variety of progressive kidney function declines, ranging from mild impairment to end-stage renal disease (ESRD). As a global public health problem, early detection and monitoring remain critical for improving patient outcomes. This study aimed to evaluate the potential diagnostic significance and interrelationships of serum sclerostin, Methods: A total of 150 participants were enrolled in this present case-control study: 50 hemodialysis patients, 50 CKD patients, and 50 healthy controls. Circulating serum sclerostin levels were measured using ELISA. Real-time quantitative PCR (RT-qPCR) was used to measure the circulating levels of lncRNAs ( Results: Both the CKD and hemodialysis groups displayed significantly elevated levels of all studied biomarkers compared with controls. However, the highest levels of sclerostin, lncRNAs ( Conclusion: Serum sclerostin, lncRNAs (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.